The number of people living with HIV/AIDS in China is estimated to be >600,000, and projected to rise exponentially. Based on an in depth characterization of the epidemiological situation, three candidate vaccines - an innovative DNA vaccine and two different types of recombinant vaccine viruses - encoding a synthetic , Chinese clad C (CN54) derived Envy and GagPolNef polygene will be tested in a phase 1/2 clinical trial in China. 90 selected HIV negative volunteers will be vaccinated according to different prime/boost regimens and assessed for the safety and immunogenicity of the candidate vaccines. Emphasis will be put on the characterization of (cross-clade) cellular and humoral immune responses towards different regional virus strains. The proposed project also aims to establish the necessary infrastructure for future field trials.
Call for proposalData not available
Funding SchemeCSC - Cost-sharing contracts